- Home
- ESPR vs IGD Comparison
ESPR vs IGD Comparison
Compare ESPR & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- IGD
- Stock Information
- Founded
- ESPR 2008
- IGD N/A
- Country
- ESPR United States
- IGD United States
- Employees
- ESPR N/A
- IGD N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- IGD Trusts Except Educational Religious and Charitable
- Sector
- ESPR Health Care
- IGD Finance
- Exchange
- ESPR Nasdaq
- IGD Nasdaq
- Market Cap
- ESPR 456.6M
- IGD 437.7M
- IPO Year
- ESPR 2013
- IGD N/A
- Fundamental
- Price
- ESPR $2.52
- IGD $5.56
- Analyst Decision
- ESPR Buy
- IGD
- Analyst Count
- ESPR 3
- IGD 0
- Target Price
- ESPR $8.17
- IGD N/A
- AVG Volume (30 Days)
- ESPR 5.2M
- IGD 215.3K
- Earning Date
- ESPR 11-07-2024
- IGD 01-01-0001
- Dividend Yield
- ESPR N/A
- IGD 9.15%
- EPS Growth
- ESPR N/A
- IGD N/A
- EPS
- ESPR N/A
- IGD N/A
- Revenue
- ESPR $295,451,000.00
- IGD N/A
- Revenue This Year
- ESPR $198.22
- IGD N/A
- Revenue Next Year
- ESPR $25.83
- IGD N/A
- P/E Ratio
- ESPR N/A
- IGD N/A
- Revenue Growth
- ESPR 187.12
- IGD N/A
- 52 Week Low
- ESPR $1.16
- IGD $4.60
- 52 Week High
- ESPR $3.40
- IGD $5.26
- Technical
- Relative Strength Index (RSI)
- ESPR 64.07
- IGD 53.69
- Support Level
- ESPR $2.02
- IGD $5.52
- Resistance Level
- ESPR $2.60
- IGD $5.59
- Average True Range (ATR)
- ESPR 0.19
- IGD 0.06
- MACD
- ESPR 0.02
- IGD 0.01
- Stochastic Oscillator
- ESPR 89.04
- IGD 83.33
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.